Market Trends of Penicillin Drug Industry
Broad Spectrum Segment Expects to Register a Highest CAGR in the Market Over the Forecast Period
Broad-spectrum penicillins work against a variety of disease-causing bacteria as well as the two leading bacterial types, gram-positive and gram-negative bacteria. The broad-spectrum penicillin segment is anticipated to hold a significant share of revenue in the spectrum of activity segment over the forecast period owing to factors such as the rising burden of Gram-positive and Gram-negative bacterial infections, which include pneumonia, urinary tract infections, and gonorrhea, and also with emerging new antibiotics drugs in the market. In addition, when treating Pseudomonas aeruginosa infections, broad-spectrum penicillins frequently combine with aminoglycosides due to their synergistic effects. Hence, the combination of broad-spectrum penicillins with other classes of drugs likely increases the demand for the products in the segment, thereby propelling the market growth in the study period.
The high burden of infectious diseases is anticipated to drive the market growth of broad-spectrum penicillin. For instance, according to the report by WHO in February 2023, the highest burden of meningitis is seen in a region of sub-Saharan Africa, known as the African Meningitis Belt, which is primarily recognized to be at increased risk of meningococcal but also pneumococcal meningitis epidemics. In addition, as per the same source, from 1 November 2022 to 27 January 2023, 559 cases of meningitis, including 18 deaths, were reported from the Zinder Region, southeast of Niger, West Africa. Similarly, the review article published by Microbiology Insights in November 2021 stated that the prevalence of Meningococcal meningitis in epidemic and endemic conditions was 12.1% and 0.76%. This shows the high burden of bacterial meningitis that increases the demand for broad-spectrum penicillins, thereby propelling the market's growth through this segment.
Furthermore, the rising company's focus on research and development activities to address the need for a new class of antibiotics to treat emerging resistant bacteria and related infections also contributes to the market's growth. For instance, in April 2022, Qpex Biopharma, Inc. presented new phase 1 clinical data for their β-lactamase inhibitor xeruborbactam (formerly QPX7728) that is co-administered with beta-lactam antimicrobials which are expected to have new broad-spectrum penicillin combinations that drive the market to grow over the forecast period. Therefore, the studied segment is expected to grow significantly over the forecast period due to the factors above.
North America is Expected to have Significant Share in the Market Over the Forecast Period
North America is expected to hold a significant share of the overall market over the forecast period owing to factors such as the rising prevalence of infectious diseases, the presence of better healthcare infrastructure along with key market players, and increasing awareness programs. Additionally, the growing elderly and pediatric populations in the area, more vulnerable to contracting infectious diseases because of low immunity, are anticipated to support the market's growth.
For instance, according to the National Foundation for Infectious Diseases, updated in March 2022, pneumococcal pneumonia causes an estimated 150,000 hospitalizations annually in the United States. Similarly, as per the report published by the Public Health Agency of Canada in December 2022, in Canada, 11,268 cases of infectious syphilis were reported in 2021 for a rate of 30 per 100,000 population, which was an increase of 20% compared with the previous year's. This illustrates the rise in bacterial infections in the region, which increases the demand for antibiotics like penicillin and likely contributes to the market's growth.
Moreover, the rising company's focus on producing antibiotics like penicillin for treating various infectious diseases is also contributing to the market's growth. For instance, in November 2021, US Antibiotics relaunched the production of the amoxicillin manufacturing facility. This is to boost the production of Amoxicillin products to meet the nation's demand for essential medications. Thus, the market is projected to grow over the forecast period due to the developments above and the increasing burden of infectious diseases in the region.
